Gynecologic Cancer
Conference Coverage
SRS instead of WBRT for patients with multiple brain metastases
Conference Coverage
Cancer therapy affects sexual health in most patients
Opinion
Are uterine manipulators safe for gynecologic cancer surgery?
Prospective studies are needed to determine if use of these instruments truly is safe or not.
Guidelines
ASCO advises against PARP inhibitor retreatment in ovarian cancer
ASCO guidelines detail recommendations for PARP inhibitor treatment in ovarian cancer.
From the Journals
‘Tour de force’ study reveals therapeutic targets in 38% of cancer patients
The NCI-MATCH trial has led to new clinical trial benchmarks, according to the study chair.
Conference Coverage
Lower BP and better tumor control with drug combo?
Feature
Are oncologists ready to confront a second wave of COVID-19?
From the Journals
Two-stage surgery to reduce ovarian cancer risk piques interest
Conference Coverage
Clinical factors and treatment tied to COVID-19 mortality in cancer patients
Analyses of CCC19 data revealed factors linked to mortality in patients with COVID-19 and cancer.
Conference Coverage
Atezolizumab strikes out in ovarian cancer
Atezolizumab did not extend progression-free survival.
From the Journals
HPV vaccine shown to substantially reduce cervical cancer risk
A review of more than 1 million girls/women vaccinated in 2006-2017 shows a substantial reduction in the risk for invasive cervical cancer.